Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 285.16 Billion KRW | 5.98% |
| 2022 | 250.58 Billion KRW | 12.12% |
| 2021 | 223.48 Billion KRW | 16.73% |
| 2020 | 191.45 Billion KRW | 4.09% |
| 2019 | 183.93 Billion KRW | 12.39% |
| 2018 | 163.65 Billion KRW | -1.88% |
| 2017 | 166.79 Billion KRW | 7.9% |
| 2016 | 154.59 Billion KRW | 9.3% |
| 2015 | 141.43 Billion KRW | 4.2% |
| 2014 | 135.73 Billion KRW | 11.45% |
| 2013 | 121.78 Billion KRW | -0.96% |
| 2012 | 122.96 Billion KRW | 5.42% |
| 2011 | 116.64 Billion KRW | 12.42% |
| 2010 | 103.76 Billion KRW | 5.43% |
| 2009 | 98.42 Billion KRW | 12.67% |
| 2008 | 87.35 Billion KRW | 2.11% |
| 2007 | 85.55 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 69.45 Billion KRW | 2.92% |
| 2024 Q3 | 251.57 Billion KRW | 3.37% |
| 2024 Q1 | 67.47 Billion KRW | -19.19% |
| 2023 Q4 | 83.5 Billion KRW | 231.09% |
| 2023 Q1 | 63.33 Billion KRW | -7.75% |
| 2023 Q3 | -63.7 Billion KRW | 9.13% |
| 2023 FY | 265.56 Billion KRW | 5.98% |
| 2023 Q2 | -70.1 Billion KRW | -210.69% |
| 2022 Q2 | 62.42 Billion KRW | 205.12% |
| 2022 FY | 250.58 Billion KRW | 12.12% |
| 2022 Q4 | 68.64 Billion KRW | 14.19% |
| 2022 Q3 | 60.11 Billion KRW | -3.7% |
| 2022 Q1 | -59.38 Billion KRW | -197.05% |
| 2021 Q2 | 56.06 Billion KRW | 2.06% |
| 2021 Q1 | 54.93 Billion KRW | 2.48% |
| 2021 FY | 223.48 Billion KRW | 16.73% |
| 2021 Q3 | 51.29 Billion KRW | -8.49% |
| 2021 Q4 | 61.19 Billion KRW | 19.29% |
| 2020 Q1 | 40.93 Billion KRW | -18.05% |
| 2020 FY | 191.45 Billion KRW | 4.09% |
| 2020 Q3 | 49.55 Billion KRW | 4.61% |
| 2020 Q4 | 53.6 Billion KRW | 8.18% |
| 2020 Q2 | 47.36 Billion KRW | 15.7% |
| 2019 Q2 | 45.12 Billion KRW | 8.9% |
| 2019 FY | 183.93 Billion KRW | 12.39% |
| 2019 Q1 | 41.43 Billion KRW | 11.9% |
| 2019 Q3 | 47.41 Billion KRW | 5.07% |
| 2019 Q4 | 49.95 Billion KRW | 5.36% |
| 2018 Q4 | 37.03 Billion KRW | -13.05% |
| 2018 Q3 | 42.58 Billion KRW | -8.75% |
| 2018 FY | 163.65 Billion KRW | -1.88% |
| 2018 Q2 | 46.67 Billion KRW | 24.9% |
| 2018 Q1 | 37.36 Billion KRW | -19.56% |
| 2017 Q3 | 41.2 Billion KRW | -4.01% |
| 2017 Q4 | 46.45 Billion KRW | 12.75% |
| 2017 FY | 166.79 Billion KRW | 7.9% |
| 2017 Q1 | 36.21 Billion KRW | -4.97% |
| 2017 Q2 | 42.92 Billion KRW | 18.54% |
| 2016 FY | 154.59 Billion KRW | 9.3% |
| 2016 Q2 | 40.25 Billion KRW | 11.52% |
| 2016 Q3 | 40.13 Billion KRW | -0.3% |
| 2016 Q4 | 38.1 Billion KRW | -5.06% |
| 2016 Q1 | 36.09 Billion KRW | -6.87% |
| 2015 Q4 | 38.76 Billion KRW | 8.08% |
| 2015 Q2 | 35.82 Billion KRW | 15.62% |
| 2015 Q1 | 30.98 Billion KRW | -16.14% |
| 2015 FY | 141.43 Billion KRW | 4.2% |
| 2015 Q3 | 35.86 Billion KRW | 0.1% |
| 2014 Q1 | 30.15 Billion KRW | -7.72% |
| 2014 Q3 | 32.87 Billion KRW | -8.05% |
| 2014 Q4 | 36.94 Billion KRW | 12.4% |
| 2014 Q2 | 35.75 Billion KRW | 18.55% |
| 2014 FY | 135.73 Billion KRW | 11.45% |
| 2013 Q2 | 30.49 Billion KRW | 13.23% |
| 2013 Q4 | 32.68 Billion KRW | 3.15% |
| 2013 FY | 121.78 Billion KRW | -0.96% |
| 2013 Q1 | 26.92 Billion KRW | -17.64% |
| 2013 Q3 | 31.68 Billion KRW | 3.91% |
| 2012 FY | 122.96 Billion KRW | 5.42% |
| 2012 Q1 | 31.13 Billion KRW | 7.89% |
| 2012 Q4 | 32.69 Billion KRW | 11.66% |
| 2012 Q3 | 29.28 Billion KRW | -1.84% |
| 2012 Q2 | 29.83 Billion KRW | -4.17% |
| 2011 Q4 | 28.85 Billion KRW | -1.42% |
| 2011 FY | 116.64 Billion KRW | 12.42% |
| 2011 Q3 | 29.27 Billion KRW | -6.45% |
| 2011 Q2 | 31.28 Billion KRW | 13.76% |
| 2011 Q1 | 27.5 Billion KRW | 0.35% |
| 2010 Q2 | 26.08 Billion KRW | -0.18% |
| 2010 Q1 | 26.13 Billion KRW | -5.97% |
| 2010 FY | 103.76 Billion KRW | 5.43% |
| 2010 Q4 | 27.4 Billion KRW | 11.95% |
| 2010 Q3 | 24.48 Billion KRW | -6.14% |
| 2009 Q3 | 23.75 Billion KRW | 5.18% |
| 2009 Q1 | 24.29 Billion KRW | 16.94% |
| 2009 Q2 | 22.58 Billion KRW | -7.02% |
| 2009 Q4 | 27.78 Billion KRW | 16.97% |
| 2009 FY | 98.42 Billion KRW | 12.67% |
| 2008 Q4 | 20.77 Billion KRW | -7.03% |
| 2008 Q1 | 21.45 Billion KRW | -11.71% |
| 2008 Q2 | 23.3 Billion KRW | 8.64% |
| 2008 FY | 87.35 Billion KRW | 2.11% |
| 2008 Q3 | 22.34 Billion KRW | -4.12% |
| 2007 FY | 85.55 Billion KRW | 0.0% |
| 2007 Q2 | 20.81 Billion KRW | -2.47% |
| 2007 Q4 | 24.29 Billion KRW | 20.8% |
| 2007 Q1 | 21.34 Billion KRW | 0.0% |
| 2007 Q3 | 20.11 Billion KRW | -3.38% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -503.467% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 4.305% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -2.415% |
| HANDOK Inc. | 153.76 Billion KRW | -85.449% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -312.003% |
| Yuhan Corporation | 489.94 Billion KRW | 41.797% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 7.101% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -582.377% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 53.326% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -296.15% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -63.746% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -611.959% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -204.818% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -148.561% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -503.467% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -571.416% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -279.967% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -386.257% |
| JW Holdings Corporation | 301.25 Billion KRW | 5.343% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -9.276% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 30.22% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -19.359% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -123.36% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -317.447% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -333.697% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -63.018% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -503.467% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -14.467% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 49.117% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -19.359% |
| Yuhan Corporation | 489.94 Billion KRW | 41.797% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -47.246% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -310.491% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -408.927% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -19.359% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -125.616% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -141.225% |
| CKD Bio Corp. | 25.19 Billion KRW | -1031.786% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -28.452% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -72.707% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -329.348% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -123.36% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 18.691% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -225.743% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -63.746% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1307.403% |